December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals, Inc. - Common Stock (NQ:DAWN)

21.38 -0.07 (-0.30%)
Streaming Delayed Price Updated: 2:31 PM EDT, Mar 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Day One Biopharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Bank of America Says Buy These 3 Stocks for a Double-Digit Rally ↗
Despite fears of a recession roiling the markets, analysts say these are the best stocks to buy with an average upside potential of 72%. 
Via InvestorPlace
Topics Economy
News headline image
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Analyst Ratings for Day One Biopharmaceutical ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Day One Biopharmaceutical ↗
 
Via Benzinga
News headline image
Where Day One Biopharmaceutical Stands With Analysts ↗
 
Via Benzinga
News headline image
DAWN Stock Earnings: Day One Biopharmaceutical Beats EPS, Beats Revenue for Q2 2024 ↗
DAWN stock results show that Day One Biopharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Oversubscribed $175.0 Million Private Placement
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal ↗
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting... 
Via Talk Markets
News headline image
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Sale of Priority Review Voucher for $108 Million
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024 ↗
DAWN stock results show that Day One Biopharmaceutical missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Two New Appointments to Board of Directors
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting 
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dow Up Over 340 Points As Stocks Snap Back ↗
The Dow Jones Industrial Average is building on this morning's gains, up 343 points at last look, while the S&P 500 and Nasdaq Composite sit firmly in the black as well. 
Via Talk Markets
Topics Stocks
News headline image
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Priority review granted with PDUFA target action date of April 30, 2024 
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
$15M Bet On Day One Biopharmaceuticals? Check Out These 3 Stocks Insiders Are Buying ↗
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
News headline image
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.